Literature DB >> 9864731

Japanese Creutzfeldt-Jakob disease patients exhibiting high incidence of the E200K PRNP mutation and located in the basin of a river.

T Miyakawa1, K Inoue, E Iseki, C Kawanishi, N Sugiyama, H Onishi, Y Yamada, K Suzuki, K Iwabuchi, K Kosaka.   

Abstract

Seven cases with Creutzfeldt-Jakob disease (CJD) located in the basin of the Fuji river (Fuji area) in Japan were examined genetically and clinicopathologically. The onset of the disease was between 1989 and 1995. All cases were from different families, although 3 cases were family members of previously reported CJD patients. They had clinical and/or neuropathological features, corresponding to subacute spongiform encephalopathy. Five of the 7 cases, including the 3 familial cases, had the E200K mutation in the gene encoding prion protein (PRNP). It is suggested that there is a small cluster of CJD patients with a founder effect of the E200K mutation in the Fuji area, because the incidence of CJD with the E200K mutation appears to be much higher in this area than other areas in Japan. The disease penetrance of the 5 cases with the E200K mutation seems to be low, and they may have an age-related incidence in the Fuji area. These findings support the hypothesis that the phenotypes of CJD patients with the PRNP mutations are linked to the position of the mutation, but not related to ethnic or environmental factors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9864731     DOI: 10.1080/01616412.1998.11740584

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  7 in total

1.  Molecular evidence of founder effects of fatal familial insomnia through SNP haplotypes around the D178N mutation.

Authors:  Ana B Rodríguez-Martínez; Miguel A Alfonso-Sánchez; José A Peña; Raquel Sánchez-Valle; Inga Zerr; Sabina Capellari; Miguel Calero; Juan J Zarranz; Marian M de Pancorbo
Journal:  Neurogenetics       Date:  2008-03-18       Impact factor: 2.660

2.  Genetic prion disease: the EUROCJD experience.

Authors:  Gábor G Kovács; Maria Puopolo; Anna Ladogana; Maurizio Pocchiari; Herbert Budka; Cornelia van Duijn; Steven J Collins; Alison Boyd; Antonio Giulivi; Mike Coulthart; Nicole Delasnerie-Laupretre; Jean Philippe Brandel; Inga Zerr; Hans A Kretzschmar; Jesus de Pedro-Cuesta; Miguel Calero-Lara; Markus Glatzel; Adriano Aguzzi; Matthew Bishop; Richard Knight; Girma Belay; Robert Will; Eva Mitrova
Journal:  Hum Genet       Date:  2005-11-15       Impact factor: 4.132

3.  Ancestral origins and worldwide distribution of the PRNP 200K mutation causing familial Creutzfeldt-Jakob disease.

Authors:  H S Lee; N Sambuughin; L Cervenakova; J Chapman; M Pocchiari; S Litvak; H Y Qi; H Budka; T del Ser; H Furukawa; P Brown; D C Gajdusek; J C Long; A D Korczyn; L G Goldfarb
Journal:  Am J Hum Genet       Date:  1999-04       Impact factor: 11.025

4.  Creutzfeldt-Jakob disease with E200K PRNP mutation: a case report and revision of the literature.

Authors:  Michelangelo Mancuso; Gabriele Siciliano; Sabina Capellari; Daniele Orsucci; Policarpo Moretti; Giuseppe Di Fede; Silvia Suardi; Rosaria Strammiello; Piero Parchi; Fabrizio Tagliavini; Luigi Murri
Journal:  Neurol Sci       Date:  2009-07-14       Impact factor: 3.307

5.  Spatial clusters of Creutzfeldt-Jakob disease mortality in Japan between 1995 and 2004.

Authors:  Y Doi; T Yokoyama; M Sakai; Y Nakamura; T Tango; K Takahashi
Journal:  Neuroepidemiology       Date:  2008-04-18       Impact factor: 3.282

6.  Age at Death of Creutzfeldt-Jakob disease in subsequent family generation carrying the E200K mutation of the prion protein gene.

Authors:  Maurizio Pocchiari; Anna Poleggi; Maria Puopolo; Marco D'Alessandro; Dorina Tiple; Anna Ladogana
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

7.  Descriptive epidemiology of prion disease in Japan: 1999-2012.

Authors:  Yosikazu Nakamaura; Ryusuke Ae; Ichiro Takumi; Nobuo Sanjo; Tetsuyuki Kitamoto; Masahito Yamada; Hidehiro Mizusawa
Journal:  J Epidemiol       Date:  2014-10-04       Impact factor: 3.211

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.